Under the terms of the alliance, IGI Laboratories will develop and manufacture prescription topical drug products owned by Medimetriks Pharmaceuticals.
Medimetriks has appointed IGI as Medimetriks’ authorized generic distributor of certain products in this line.
Medimetriks is likely to introduce a new portfolio of prescription topical brands in the second quarter of 2012, whose authorized generic distribution will begin shortly thereafter by IGI Laboratories.
IGI CEO Charlie Moore said the collaboration marks a key step in IGI Laboratories’ expansion into a fully-integrated developer and manufacturer of prescription topical pharmaceuticals.
"This partnership provides IGI the opportunity to enhance our relationship with a strong brand marketer as well as providing marketing opportunities as the authorized generic," Moore added.
Â